Crown Bioscience Announces Transaction Closing of Indivumed’s Service Business and Supporting Biobank
Crown Bioscience, a global contract research organization (CRO) and JSR Life Sciences company, announced today that it has completed its acquisition of the IndivuServ business unit of Indivumed Gmb...
Crown Bioscience opens Singapore Laboratory and Establishes Local Commercial Partner
The new facility expands the company’s capacity to support both global and local biotech and pharma companies engaged in preclinical and translational oncology drug discovery and development.
Crown Bioscience to Acquire Indivumed’s Service Business and Supporting Biobank
Acquisition expands global service offering to include access and analysis of unique clinical biospecimens
Crown Bioscience Publishes New Study in PLOS ONE Highlighting the Use of Clinically Relevant 3D In Vitro PDX-Derived ...
Crown Bioscience announced today their newly published study in PLOS ONE demonstrating the establishment and application of a clinically relevant 3D in vitro PDX-derived organoid biobank for higher...
Crown Bioscience and ERS Genomics Announce Global CRISPR/Cas9 Licensing Agreement for Genome Editing Patents
Crown Bioscience have signed a global license agreement for access to the foundational CRISPR/Cas9 patent portfolio held by ERS, which provides the company full license to operate globally using CR...
New Crown Bioscience Publication Details Application of In Vitro 3D Organoids with Matched PDX for Clinically Relevan...
The paper is the first comprehensive review of tumor organoids derived from Patient Derived Xenograft (PDX) models across multiple cancer types.
Crown Bioscience & MBL Launch Joint Venture to Serve Japanese Biopharmaceutical Community
Crown Bioscience & MBL, a joint venture between two JSR Life Sciences companies formed earlier this year, announce today the launch of their full-service drug discovery and development capabilities...
Crown Bioscience Appoints Michael Prosser as Chief Business Officer and Illustrates Further Investment in Commercial ...
Crown Bioscience announced today that it has restructured its commercial leadership team by creating a new Chief Business Officer (CBO) role and with additional investment in commercial talent.
Crown Bioscience and MBL Enter Joint Venture to Provide Advanced Preclinical Services for Japanese Customers
Crown Bioscience and MBL announce the formation of a joint venture, to further expand the provision of Crown Bioscience’s preclinical services to Japanese customers.
First Clinical Candidate Developed using HUB Organoids® and High Content Screening Targets Cancer Stem Cells in Solid...
Crown Bioscience, a JSR Life Sciences company, and HUB Organoids (HUB) announced today the publication of preclinical data in the journal, Nature Cancer, on a bispecific antibody which prevents the...